Roscrea biopharma firm secures $100m investment ahead of plans for IPO

The Tipperary-based company aims to list on the US stock market within the coming months and believes its new drug candidates are worth at least $1 billion

Peter Milner, founder, Renexxion: the Roscrea biopharma company has secured $100 million (€92.5 million) in funding as part of a move that will see it list on the US stock market within the coming months